FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
A new division has been established by DiagnaMed Holdings (CSE: DMED) to focus on the development and commercialization of generative AI. Referred to as Health GenAI, the division is set to host a suite of products driven by GPT-4.
The goal of Health GenAI is to support the healthcare market in improving patient outcomes, efficiency, and operational workflow via a suite of programs powered by artificial intelligence. DiagnaMed has indicated it intends to launch at least three products from the new division this year alone.
“We are passionate about developing new generative AI-powered SaaS products to serve the needs of the healthcare sector. With the launch of our new division, Health GenAI, we are focusing on commercializing at least three generative AI solutions for the healthcare market and on complementing CERVAI™, our generative AI brain health platform,” stated CEO Fabio Chianelli of the announcement.
WATCH: DiagnaMed Brings AI To Brain Health — With Fabio Chianelli And Dr. John Kounios
The recently announced FormGPT, which is described as a generative AI data collection and analysis tool for the healthcare industry, is to be housed under the new division. The product enables professionals in the healthcare space to create customized forms and surveys to collect relevant patient data, provide pre-and-post visit treatment feedback, monitor patient progress, and to analyze results.
DiagnaMed’s CERVAI meanwhile will be housed under a separate division. CERVAI is the firms generative AI brain health platform, which lead to the development of FormGPT.
DiagnaMed last traded at $0.095 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
